Immunosuppressants Market Demand, Size, Share & Forecast 2032

Global Immunosuppressants Market Insights

According to the report published by Zion Market Research, the global Immunosuppressants Market size was valued at USD 27.79 Billion in 2023 and is predicted to reach USD 94.76 Billion by the end of 2032. The market is expected to grow with a CAGR of 14.6% during the forecast period. The report analyzes the global Immunosuppressants Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Immunosuppressants Market.

Request Free Sample

Global Immunosuppressants Market: Overview

An immunosuppressant stops the immune system from damaging healthy tissues and cells by slowing down or ceasing the response of the immune system that mistakenly attacks the healthy tissues and cells. They are usually prescribed to people with bone marrow or stem cell transplants and organ transplants to prevent transplanted tissues and organs. Immunosuppressants are also used to treat autoimmune disorders.

Global Immunosuppressants Market: Growth Factors

The global immunosuppressants market is growing at a speedy rate. Rise in focus on the development of monoclonal antibodies, growing demand for generic drugs, and increase in the prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, & psoriasis are some of the essential factors that are spurring the growth of the global market. Further, the rise in the number of organ transplants is the key factor that is boosting the growth of the market. In 2018, the predicted number of organ transplants was more than 146,000, and nearly two-thirds of them were kidney transplants. In 2020, more than 39,000 organ transplants were performed in the US alone and as of Feb 2021, it is estimated that over 107,000 numbers of children, women, and men are on the national transplant waiting list.

In addition to this, there is a surge in the number of chronic kidney diseases leading to the rise in the number of kidney transplants and growing cases of acute leukemia, refractory anemia, & osteopetrosis necessitating stem cell transplants. Such a huge burden of organ transplants has led to the surge in the demand for immunosuppressants thereby fostering the growth of the global immunosuppressants market. In addition to this, the rise in the number of clinical trials, growing mergers & acquisitions for the expansion of pipeline drugs, and rapid expansion of CDMOs & CROs supporting the discovery & development of the drugs are also some of the crucial factors that are contributing to the overall growth of the market. Moreover, factors such as an increase in healthcare expenditure and the development of healthcare infrastructure in developing countries are also aspects that are propelling the growth of the global market. Furthermore, advancements in technologies to understand molecular processes will enhance the discovery of innovative immunosuppressant drugs and offer several opportunities for the growth of the global immunosuppressants market over the forecast period. However, strict regulations regarding quality, clinical, and non-clinical aspects for the approval of immunosuppressant drugs may hinder the growth of the global immunosuppressants market.

The transplant surgeries, organ transplants, and related surgeries were suspended or postponed during the COVID-19 pandemic due to strict measures such as complete lockdown and restrictions on movement taken to avert the spread of the virus. The decision to temporarily suspend the organ transplant program was taken as the people undergoing transplant are at a high risk of contracting the infection. Thus, all these factors coupled with the shift of healthcare workers towards the treatment of Covid-19 patients have impacted the growth of the global immunosuppressants market amid the Covid-19 pandemic.

Key Insights

• As per the analysis shared by our research analyst, the global Immunosuppressants Market is estimated to grow annually at a CAGR of around 14.6% over the forecast period (2024-2032).
• In terms of revenue, the global Immunosuppressants Market size was valued at around USD 27.79 Billion in 2023 and is projected to reach USD 94.76 Billion by 2032.
• Based on the indication, In the immunosuppressants market, autoimmune diseases represent the most dominant segment by indication. The growing incidence of conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease has significantly fueled demand for immunosuppressive therapies. Additionally, increased awareness, better diagnostic rates, and advancements in treatment options have strengthened the dominance of this segment over others like organ transplantation and others.
• Based on the drug class, When segmented by drug class, calcineurin inhibitors such as cyclosporine and tacrolimus hold the largest share of the immunosuppressants market. Their effectiveness in preventing organ rejection and treating autoimmune conditions, coupled with long-standing clinical trust and widespread prescription, have made this drug class the most dominant. Ongoing developments and modifications to improve safety profiles further support their market leadership.
• Based on the distribution channel, hospital pharmacies dominate the immunosuppressants market. Due to the critical nature of these medications and the need for careful monitoring and management, many patients receive prescriptions and initial treatments directly through hospital systems. This control ensures proper administration, patient education, and handling of side effects, reinforcing the dominance of hospital pharmacies over retail and online channels.
• Based on the region, North America is the most dominant region in the immunosuppressants market. Factors like a high prevalence of autoimmune diseases, a strong healthcare infrastructure, advanced research and development activities, and a high level of awareness and access to treatment options contribute significantly to North America's leadership. The United States, in particular, plays a major role in this dominance due to its large patient population and substantial healthcare expenditure.

Global Immunosuppressants Market: Report Scope

Global Immunosuppressants Market: Segmentation

Request Free Sample

The global immunosuppressants market is bifurcated based on indication, drug class, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

Based on indication, the global immunosuppressants market is categorized into non-autoimmune inflammatory diseases, autoimmune disorders, and organ transplantation.

The drug class segment consists of anti-proliferative agents, mTOR inhibitors, calcineurin inhibitors, monoclonal antibodies (mAbs), corticosteroids, and others.

Online pharmacies, retail pharmacies, and hospital pharmacies are the distribution channels in the global market.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Global Immunosuppressants Market: Regional Analysis

Request Free Sample

Based on the region, North America is projected to lead the global immunosuppressants market during the forecast period. Factors such as growing incidences of organ transplants, heavy investment in immunosuppressant drug discovery, and favorable reimbursement policies are boosting the growth of the market in this region. Asia Pacific is expected to register the fastest growth owing to an increase in healthcare expenditure, emerging market players attracted towards India & China for business expansion, and government initiatives to undergo a kidney transplant in low & middle-income countries.

Global Immunosuppressants Market: Competitive Players

Some of the major players operating in the global immunosuppressants market include;

• Astellas Pharma, Inc
• Sanofi S.A
• Pfizer Inc.
• Novartis AG
• Mylan Laboratories Inc.
• Johnson & Johnson
• Intas Pharmaceuticals Ltd.
• GlaxoSmithKline Plc.
• F. Hoffmann La Roche Ltd.
• Bristol Myers Squibb

Global Immunosuppressants Market: Segmentation

The global immunosuppressants market is segmented as follows;

Global Immunosuppressants Market: By Indication Segment Analysis

• Non-Autoimmune Inflammatory Diseases
• Autoimmune Disorders
• Organ Transplantation

Global Immunosuppressants Market: By Drug Class Segment Analysis

• Anti-Proliferative Agents
• mTOR Inhibitors
• Calcineurin Inhibitors
• Monoclonal Antibodies (MABS)
• Corticosteroids
• Others

Global Immunosuppressants Market: By Distribution Channels Segment Analysis

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Global Immunosuppressants Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.